Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study

References

• Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:314–321.
   PubMed Web of Science ®Google Scholar
• Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61:1373–1378.
   PubMed Web of Science ®Google Scholar
• Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12:405–416.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–783.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, editors. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer- Verlag; 2005.
   Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for longterm treatment of psoriatic arthritis: forty-eight week data from the Adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–488.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33:833–839.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Spadaro A, Marchesoni A, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol. 2011;29:80–84.
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwel PS. Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.
   PubMed Web of Science ®Google Scholar
• Coates L, Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62:965–969.
   PubMed Web of Science ®Google Scholar
• Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62:970–976.
   PubMed Web of Science ®Google Scholar
• Haddad A, Thavaneswaran A, Ruiz-Arruza I, et al. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67:842–847.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–991.
   PubMed Web of Science ®Google Scholar
• Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272–277.
   PubMed Web of Science ®Google Scholar
• Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546–549.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Pipitone N, Marchesoni A, et al.; Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian society for rheumatology. Clin Exp Rheumatol. 2011;29:28–41.
   PubMed Web of Science ®Google Scholar
• Heuft-Dorenbosch L, Spoorenberg A, Van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62:127–132.
   PubMed Web of Science ®Google Scholar
• Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol. 2007;34:1302–1306.
   PubMed Web of Science ®Google Scholar
• Chandran V, Gottlieb A, Cook RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails and dactylitis. Arthritis Rheum. 2009;61:1235–1242.
   PubMed Web of Science ®Google Scholar
• Ranza R, Marchesoni A, Calori G, et al. The Italian version of the functional disability index of the health assessment questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol. 1993;11:123–128.
   PubMed Web of Science ®Google Scholar
• Cauli A, Gladman DD, Mathieu A, et al.; GRAPPA 3PPsA Study Group. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38:898–903.
   PubMed Web of Science ®Google Scholar
• Fransen J, Van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheum. 2005;23:93–99.
   PubMed Web of Science ®Google Scholar
• Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–818.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Parsons WJ, et al. Patient’s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332–2338.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Soriano E, Fitzgerald O. Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol. 2013;31:54–58.
   PubMed Web of Science ®Google Scholar
• Ma MH, Scott IC, Kingsley GH, et al. Remission in early rheumatoid arthritis. J Rheumatol. 2010;37:1444–1453.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol. 2015;42:258–263.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford). 2013;52:1914–1919.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43:350–355.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Heckaman M, Kary S, et al. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol. 2013;40:647–652.
   PubMed Web of Science ®Google Scholar
• Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:813–817.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43:371–375.
   PubMed Web of Science ®Google Scholar